Italian Multiple Sclerosis Foundation Report issue

Foundation Phase 3

Organization Overview

First Clinical Trial
2001
NCT00202410
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Italian Multiple Sclerosis Association and Foundation | Italian Multiple Sclerosis Foundation

Active Ingredients

Drugs in Phase 3 Trials (2)

bacille calmette-guerin (1 trial)

interferon beta-1b (betaseron) (1 trial)

Drugs in Other Trials (1)

osmotin (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Multiple Sclerosis (Phase 3)

Sclerosis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 3